Aquestive Therapeutics (NASDAQ:AQST) Posts Earnings Results, Beats Estimates By $0.07 EPS

Aquestive Therapeutics (NASDAQ:AQST) released its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07, FiscalAI reports. The firm had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million.

Aquestive Therapeutics Price Performance

Shares of AQST traded down $0.03 during trading hours on Wednesday, hitting $4.13. The company’s stock had a trading volume of 2,411,052 shares, compared to its average volume of 3,582,098. The company has a market cap of $513.32 million, a price-to-earnings ratio of -5.29 and a beta of 1.50. The business has a 50 day simple moving average of $4.15 and a two-hundred day simple moving average of $4.82. Aquestive Therapeutics has a 52-week low of $2.14 and a 52-week high of $7.55.

Analyst Upgrades and Downgrades

AQST has been the topic of a number of recent analyst reports. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target on the stock. Finally, Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $8.80.

Insider Transactions at Aquestive Therapeutics

In other news, insider Lori J. Braender sold 40,102 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $167,225.34. Following the completion of the transaction, the insider owned 442,879 shares in the company, valued at $1,846,805.43. This trade represents a 8.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter E. Boyd sold 29,814 shares of Aquestive Therapeutics stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $124,324.38. Following the completion of the transaction, the insider owned 338,509 shares of the company’s stock, valued at $1,411,582.53. The trade was a 8.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 395,690 shares of company stock valued at $1,650,027. 6.81% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the business. Victory Capital Management Inc. grew its stake in Aquestive Therapeutics by 17.0% during the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after acquiring an additional 1,862 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after acquiring an additional 2,649 shares in the last quarter. Informed Momentum Co LLC grew its stake in Aquestive Therapeutics by 1.8% during the fourth quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock valued at $1,002,000 after acquiring an additional 2,721 shares in the last quarter. Stifel Financial Corp grew its stake in Aquestive Therapeutics by 0.9% during the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock valued at $2,388,000 after acquiring an additional 3,300 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in Aquestive Therapeutics by 6.8% during the fourth quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after acquiring an additional 3,934 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.